A phase 1 study of CAN2109, a novel,long-acting, tumor-retained, immunogenic cell death inducer

CAN2109 - Canwell Biotech

https://www.abstractsonline.com/pp8/#!/21436/presentation/12171

Herui Yao1; Ning Li2; Henry Ninghui Yu3; Giorgio Massimini3; Jianli Zhao1; Shuhang Wang2; Yiming Zhao1; Yue Yu2; Xiuping Lai1; Xiaozhi Lv1; Shaoshan Wang3; Xia Guo3; Jiancheng Huang3; Fei Tan3; Erwei Song1

Mar 18, 2026